Nasdaq:US$15.83 (+0.59) | HKEX:HK$25.05 (+0.65) | AIM:£2.60 (+0.07)
搜索
搜索結果
上一篇文章   |   下一篇文章
公告及新聞稿, 腫瘤學 / 免疫學 | 2008-02-29

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate